Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1)

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue 3, 2002, Pages 243-248

  Van Bergeijk, Jeroen D ^a   Wilson, J H Paul ^a   Nielsen, Ole Haage ^a   Von Tirpitz, Christian ^a   Karvonen, Anna Lusa ^a   Lygren, I ^a   Rädler, Andreas ^a   Waldum, Helge L ^a   Mulder, Chris J J ^a   Friis, S ^a   Tefera, Solomon ^a   Hoogkamer, Johannes F W ^a  

^a GELDERSE VALLEI HOSPITAL   (Netherlands)

Author keywords

Neuropeptide; Octreotide; Somatostatin; Therapy; Ulcerative colitis

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; ACETIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; OCTREOTIDE; PLACEBO; PREDNISOLONE; PREDNISONE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENDOSCOPY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; MALE; MESALAMINE; OCTREOTIDE; PREDNISOLONE; PREDNISONE; SEVERITY OF ILLNESS INDEX;

EID: 0036201649     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200203000-00007     Document Type: Article

References (24)

1. Inflammatory bowel disease
2. Prognostic considerations in idiopathic inflammatory bowel disease
3. Somatostatin and the immune and haematopoietic system; a review
4. Somatostatin in the idiopathic inflammatory bowel diseases
5. Decreased somatostatin (SS) generation by colonic mucosa in active ulcerative colitis
6. Octreotide effectively decreases mucosal damage in experimental colitis
7. A comparison of oral prednisone given as single or multiple daily doses for active ulcerative colitis
8. Variations between observers in describing mucosal appearances in proctocolitis
9. Review article: The management of severe ulcerative colitis
10. New therapeutic approaches
11. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy
12. Gastrointestinal neuropeptides suppress human colonic lamina propria lymphocyte DNA synthesis
13. Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation
14. Modulatory effects of somatostatin and vaso
15. Immunomodulatory activities of the somatostatin analogue BIM 23014c: Effects on murine lymphocyte proliferation and natural killer activity
16. High affinity somatostatin receptors in the gut-associated lymphoid tissues; preferential location in germinal centers
17. Distribution of somatostatin-immunoreactive nerve fibres in Peyer's patches
18. Distribution and quantification of somatostatin in inflammatory disease
19. Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease
20. Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisolone
21. Somatostatin may participate in the antiinflammatory actions of glucocorticoids
22. Treatment of gold-induced enteritis with octreotide
23. Octreotide acetate (Sandostatin) to control the symptoms of Crohn's disease
24. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone